Osilodrostat: First Approval

doi:10.1007/s40265-020-01277-0

2020-03-05

PRE

Sean T. Duggan *

DOI：10.1007/s40265-020-01277-0

原文链接

原文求助

摘要

En 中文

Osilodrostat (Isturisa (R)) is an orally available small molecule 11 beta-hydroxylase inhibitor that is being developed by Novartis for the treatment of Cushing's disease. Based on results from a pivotal phase III trial, osilodrostat was approved in the EU for use in the treatment of endogenous Cushing's syndrome in adults and is under regulatory review in the USA for the treatment of Cushing's disease. This article summarises the milestones in the development of osilodrostat leading to this first approval.

Keyword:

11-BETA-HYDROXYLASE INHIBITOR

LCI699

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

暂无机构信息

引用论文

Molecular Differences in Skeletal Muscle After 1 Week of Active vs. Passive Recovery From High-Volume Resistance Training

Journal of Strength and Conditioning Research

IF0

2021-06-16

OAAI

Christopher G. Vann; Cody T. Haun; Shelby C. Osburn; Matthew A. Romero; Paul A. Roberson; Petey W. Mumford; C. Brooks Mobley; Hudson M. Holmes; Carlton D. Fox; Kaelin C. Young; Michael D. Roberts

Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy

International Journal of Environmental Research and Public Health

IF0

2022-12-16

OAAI

Katarzyna Zawadzka-Starczewska; Bartłomiej Stasiak; Katarzyna Wojciechowska-Durczyńska; Andrzej Lewiński; Magdalena Stasiak

Vitamin D and Diabetic Retinopathy

International Journal of Molecular Sciences

IF0

2023-07-27

OAAI

Antonela Gverović Antunica; Ljubo Znaor; Mira Ivanković; Velibor Puzović; Irena Marković; Snježana Kaštelan

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease

PITUITARY

IF3.4

2015-11-05

108

OAAI

Fleseriu, Maria; Pivonello, Rosario; Young, Jacques; Hamrahian, Amir H.; Molitch, Mark E.; Shimizu, Chikara; Tanaka, Tomoaki; Shimatsu, Akira; White, Tracy; Hilliard, Annie; Tian, Chuan; Sauter, Nicholas; Biller, Beverly M. K.; Bertagna, Xavier

LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2014-04-01

154

OAAI

Bertagna, Xavier; Pivonello, Rosario; Fleseriu, Maria; Zhang, Yiming; Robinson, Paul; Taylor, Ann; Watson, Catherine E.; Maldonado, Mario; Hamrahian, Amir H.; Boscaro, Marco; Biller, Beverly M. K.

Recent Development in Antioxidant of Milk and Its Products

Biochemistry

IF0

2023-05-03

OAAI

Fouad M.F. Elshaghabee; Ahmed A. Abd El-Maksoud; Gustavo M. Ambrósio F. de Gouveia

Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2014-12-10

OAAI

Menard, Joel; Rigel, Dean F.; Watson, Catherine; Jeng, Arco Y.; Fu, Fumin; Beil, Michael; Liu, Jing; Chen, Wei; Hu, Chii-Whei; Leung-Chu, Jennifer; LaSala, Daniel; Liang, Guiqing; Rebello, Sam; Zhang, Yiming; Dole, William P.

Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2019-04-24

OAAI

Creemers, Sara G.; Feelders, Richard A.; de Jong, Frank H.; Franssen, Gaston J. H.; de Rijke, Yolanda B.; van Koetsveld, Peter M.; Hofland, Leo J.

Differential Metabolomic Analysis of Liver Tissues from Rat Models of Parenteral Nutrition‐Associated Liver Disease

BioMed Research International

IF0

2020-03-21

OAAI

Songlin Wan; Jianbo Yang; Gulsudum Mamtawla; Li Zhang; Xuejin Gao; Xinying Wang

没有更多内容